The Sickle Cell Transitions Policy Lab was established in 2024 to drive health system change and improve outcomes for people living with Sickle Cell Disease (SCD) during the transition from paediatric to adult care. Our vision is to seamlessly bridge this gap, ensuring a continuous, coordinated, compassionate healthcare journey, optimising mental and physical well-being during this critical time.
Bringing together patient representatives, advocates, clinicians and system experts from across Europe, we co-developed solutions grounded in the lived experience of SCD and the operational realities of health systems. The resulting Charter clearly defines an optimal transition that all people with SCD should experience, wherever they live, and outlines essential steps to deliver holistic, coordinated, and continuous care.
Novo Nordisk and Pfizer commissioned and funded the production of this Charter. The Charter has been developed by the members of the Sickle Cell Transitions Policy Lab and Lived Experience Council, with support from MHP Group acting as Secretariat. The companies provided no direction on the recommendations made by the authors within the Charter. The companies did not provide substantive input to the Charter language; however, both companies have reviewed the Charter for factual accuracy and to ensure compliance with all relevant industry codes of practice, including those of the EFPIA and ABPI.
PP-LTV-GLB-0413 / HQ25SCD00015
